Scinai Immunotherapeutics has taken a major leap forward, announcing the acquisition of 100% of Recipharm Israel and a long-term strategic commercial collaboration with Recipharm. The move dramatically expands Scinai’s CDMO capabilities and global reach.

 

The acquisition brings Recipharm’s Yavne, Israel facility under Scinai’s umbrella, preserving operational continuity, employees, quality systems, regulatory approvals, and customer contracts. The Yavne site will complement Scinai’s Jerusalem operations, strengthening its end-to-end offering from early development to late-stage clinical and commercial supply.

 

“This transaction fundamentally strengthens Scinai's CDMO platform,” said Amir Reichman, Chief Executive Officer of Scinai. 

 

“By combining our early-stage development strengths with Recipharm Israel's manufacturing capabilities and Recipharm's global footprint, we are creating a differentiated offering that supports clients from early development through commercialization. Importantly, the collaboration allows Scinai to participate in the long-term success of client programs while maintaining capital discipline and operational focus.”

 

The strategic collaboration creates a seamless path for Scinai clients to transition from early-stage development to global manufacturing. Under the agreement:

 

Scinai will serve as a preferred partner for early-stage development and clinical manufacturing projects.

 

Recipharm will act as a preferred partner for late-stage clinical and commercial manufacturing.

 

Both parties will refer client projects, share economics, and align on quality, regulatory compliance, and tech transfer.

 

“Ensuring continuity for the Yavne site, its employees and its customers was a key priority for us, and we are pleased to pair that with a strategic collaboration with Scinai,” said Greg Behar, Chief Executive Officer of Recipharm. 

 

"The agreement creates a clear pathway for programs to progress efficiently into Recipharm's global development and commercial manufacturing network.”

 

The collaboration is designed to streamline transitions for smaller CDMO clients, reduce friction, and maintain service continuity as programs scale. It also allows Scinai to leverage Recipharm’s global manufacturing network, enhancing technical scope across recombinant proteins, small molecules, peptides, antibodies, and oligonucleotides.